Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
Yesterday
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.

Anticoagulation therapy lowers risk of BVD after TAVR

13 Jan 2019
A new synthetic heart has valves, arteries and veins made of polyvinyl alcohol hydrogel

Sex, renal failure and atrial fibrillation (AF) are most significantly associated with mortality at 3-year follow-up, whereas anticoagulation therapy, given mostly to AF patients, reduces the risk of bioprosthetic valve dysfunction (BVD) following transcatheter aortic valve replacement (TAVR), according to a recent study.

Overall, 12,804 patients were identified in the registry between 1 January 2013 and 31 December 2015, of whom 11,469 (mean age 82.8 years; logistic European System for Cardiac Operative Risk Evaluation, 17.8 percent; mean duration of follow-up, 495 days) were alive at discharge with known antithrombotic treatment and were included in the analysis for mortality.

There were 2,555 patients who had at least two echocardiographic assessments and were eligible for BVD evaluation. Of the patients, one-third had a history of AF and had oral anticoagulation at discharge (n=3,836).

Both aspirin and clopidogrel were not associated with mortality. The strongest independent predictors of death were male sex (adjusted hazard ratio [aHR], 1.63; 95 percent CI, 1.44–1.84; p<0.001), history of AF (aHR, 1.41; 1.23–1.62; p<0.001) and chronic renal failure (aHR, 1.37; 1.23–1.53; p<0.001).

Independently, anticoagulation at discharge (adjusted odds ratio [aOR], 0.54; 0.35–0.82; p=0.005) and a nonfemoral approach (aOR, 0.53; 0.28–1.02; p=0.49) correlated with lower BVD rates, while chronic renal failure (aOR, 1.46; 1.03–2.08; p=0.034) and prosthesis size 23 mm (aOR, 3.43; 2.41–4.89; p<0.001) were associated with increased BVD risk.

This study sought to identify independent correlates of long-term all-cause mortality and early BVD, defined as increased prosthetic gradient 10 mm Hg or new gradient ≥20 mm Hg, using FRANCE TAVI (French Transcatheter Aortic Valve Implantation), a prospective, multicentre nationwide registry.

The authors performed multiple imputations to account for missing values, as well as sensitivity analysis retaining only patients with complete data.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 06 Sep 2017

In patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI), dual antithrombotic therapy with dabigatran and a P2Y12 inhibitor significantly reduces bleeding vs triple therapy with warfarin, a P2Y12 inhibitor and aspirin, with comparable rates of thromboembolic events, results of the RE-DUAL PCI trial have shown.

19 Jun 2019
Slideshow: Highlights from the Asian Pacific Society of Cardiology 2019 Congress
Yesterday
A study has recently derived and validated a new index for preoperative cardiovascular evaluation, which can significantly contribute to the efficient triage and management of patients scheduled for noncardiac surgery. The new Cardiovascular Risk Index (CVRI) demonstrates a robust discriminatory power that can effectively stratify patients into low-, intermediate- and high-risk groups.
04 Jun 2019
The addition of alirocumab to intensive statin therapy appears to cut the risk of death following acute coronary syndrome, especially if treatment is sustained for at least 3 years, if baseline low-density lipoprotein cholesterol (LDL-C) is ≥100 mg/dL or if achieved LDL-C is low, according to data from the ODYSSEY OUTCOMES.